Oppenheimer Remains a Buy on Prestige Consumer Healthcare (PBH)

Oppenheimer analyst Rupesh Parikh maintained a Buy rating on Prestige Consumer Healthcare today and set a price target of $77.00.

Valentine's Day Sale - 70% Off

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

According to TipRanks, Parikh is a 5-star analyst with an average return of 12.1% and a 64.11% success rate. Parikh covers the Consumer Defensive sector, focusing on stocks such as Church & Dwight, Walmart, and Costco.

In addition to Oppenheimer, Prestige Consumer Healthcare also received a Buy from TipRanks – OpenAI’s OpenAI Medical – Distribution in a report issued on February 6. However, on the same day, TipRanks – Google downgraded Prestige Consumer Healthcare (NYSE: PBH) to a Hold.

Based on Prestige Consumer Healthcare’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $283.44 million and a net profit of $46.7 million. In comparison, last year the company earned a revenue of $290.32 million and had a net profit of $61.03 million

Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PBH in relation to earlier this year. Most recently, in December 2025, Jeffrey Zerillo, the SVP Operations of PBH sold 1,000.00 shares for a total of $60,000.00.